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Abstract
Immune checkpoint inhibitors have shown anti-tumour ac-
tivity in cancers such as melanoma, renal cell carcinoma, 
non-small-cell lung cancer, urothelial carcinoma, colorectal 
cancer, and Hodgkin’s lymphoma. Though immune check-
point inhibitors have revolutionized the treatment and 
prognosis of some advanced malignancies, they are also as-
sociated with a significant risk of immune-related adverse 
events. These adverse events can occur in any organ system, 
but gastrointestinal side effects are among the most com-
monly reported, with manifestations ranging from mild diar-
rhoea to severe colitis, sharing some features with inflamma-
tory bowel disease. Anticipating a greater use of these drugs 
in the future, gastroenterologists should expect to be in-
creasingly faced with gastrointestinal immune-related ad-
verse events. Knowledge of these toxicities, as well as effec-
tive management algorithms, is essential to enable early di-
agnosis and treatment, decreasing morbidity and mortality. 
We reviewed the currently available literature on gastroin-
testinal toxicity induced by immune checkpoint inhibitors, 
namely the clinical features, diagnosis, and management.
© 2018 Sociedade Portuguesa de Gastrenterologia 
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Resumo
Os inibidores dos checkpoint imunológicos demonstr-
aram atividade antitumoral em neoplasias como o mela-
noma, o carcinoma de células renais, o carcinoma pulmo-
nar de não pequenas células, o carcinoma urotelial, o car-
cinoma colorretal e o linfoma de Hodgkin. Estes fármacos, 
embora tenham revolucionado o tratamento e o prog-
nóstico de algumas neoplasias avançadas, também se as-
sociam a um risco considerável de efeitos adversos asso-
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ciados ao sistema imunitário. Qualquer órgão pode ser 
afetado, mas os efeitos adversos gastrointestinais estão 
entre os mais comumente relatados. As manifestações 
gastrointestinais variam desde diarreia ligeira a colite 
grave, a qual pode evidenciar características idênticas às 
da doença inflamatória intestinal. Antecipando uma 
maior utilização destes fármacos no futuro, os gastroen-
terologistas devem esperar confrontar-se cada vez mais 
com este tipo de efeitos adversos. O conhecimento des-
sas toxicidades, bem como dos algoritmos de aborda-
gem destes doentes é fundamental para um diagnóstico 
e tratamento precoces, diminuindo desta forma a mor-
bilidade e a mortalidade. Os autores pretenderam rever 
a literatura mais atual sobre a toxicidade gastrointestinal 
induzida pelos inibidores dos checkpoint imunológicos, 
nomeadamente apresentação clínica, abordagem diag-
nóstica e terapêutica.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Immunotherapy with monoclonal antibodies target-
ing cytotoxic T lymphocyte-associated antigen 4 (CTLA-
4) and the programmed death-1 receptor (PD-1) and its 
ligand PD-L1 have joined the list of standard and effective 
anti-tumour therapy. Therefore, an increasing number of 
patients will be exposed to these drugs creating a new set 
of challenges for clinicians, who must develop a working 
knowledge of these agents, namely how to diagnose and 
effectively manage their toxicities [1, 2].
The physiological role of immune checkpoints, such as 
CTLA-4 and PD-1, is to regulate the degree of T cell acti-
vation, to prevent exaggerated immune responses or au-
toimmunity. CTLA-4 helps maintain peripheral immune 
tolerance and regulate adaptive immune responses by 
competing with CD28 to bind the B7 receptor on antigen-
presenting cells, thus downregulating T-cell activation. 
CTLA-4 is constitutively expressed by regulatory T cells 
(Treg cells), an immunomodulatory subset of CD4+ effec-
tor T cells, which have an instrumental role in immuno-
logical tolerance. In addition to producing immunosup-
pressive cytokines, Treg cells might also affect activation 
of conventional CD4+ T cells and CD8+ T cells [3–5].
PD-1 is a cell surface co-inhibitory receptor, expressed 
on the surface of T cells, B cells, monocytes, natural killer 
T cells, and dendritic cells. In T cells, expression and lo-
calization of PD-1 to the cell surface requires activation 
through the T-cell receptor (TCR) and cytokine signal-
ing. Binding of PD-L1 to PD-1 triggers the inhibition of 
the TCR signaling pathway and reduces the expression 
and production of cytokines and transcription factors 
that are associated with effector T-cell function. The PD-1 
pathway might also promote Treg cell suppression and 
has been implicated as an important checkpoint in the 
activation and development of innate lymphoid cells, in-
volved as significant effector cells at mucosal surfaces and 
especially the gut [3–5].
Given the central role of host immunity in the detec-
tion, recognition, and deletion of emergent neoplastic 
cells, targeting pathways that intrinsically inhibit T-cell 
activation was conceived as an attractive therapeutic 
strategy [5]. Nevertheless, a disruption in the functioning 
of immune checkpoint molecules can lead to imbalances 
in immunologic tolerance, which may manifest with 
autoimmune-like/inflammatory side-effects, designated 
immune-related adverse events (irAEs) [2].
In recent years, targeted immunotherapy against these 
immune checkpoints has been widely explored and is 
now approved by the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) for 
the treatment of advanced melanoma, non-small cell lung 
carcinoma, renal cell carcinoma, colorectal carcinoma, 
Hodgkin’s lymphoma, and urothelial carcinoma [1, 3, 5]. 
Approved immune checkpoint inhibitors (ICPIs) include 
five anti-PD-1 antibodies (nivolumab, pembrolizumab, 
atezolizumab, avelumab, and durvalumab) and one 
CTLA-4 inhibitor (ipilimumab) [3, 5].
Knowledge of toxicities associated with immunother-
apy, as well as effective management algorithms for these 
toxicities, is pivotal in order to optimize clinical efficacy 
and safety. In this review, we describe gastrointestinal 
toxicity from checkpoints inhibitors targeting CTLA-4 
and PD-1 and provide general recommendations for the 
appropriate management of these irAEs.
Epidemiology
Gastrointestinal toxicity is one of the most frequent 
and often the most severe of irAEs associated with anti-
CTLA-4, leading to its discontinuation [6]. About one-
third of patients treated with anti-CTLA-4 have irAEs of 
the gastrointestinal tract, including aphthous ulcers, 
esophagitis, gastritis, diarrhoea, and colitis. The frequen-
cy of colitis ranges from 8% to 22% [7]. In a large study 
including 676 patients, diarrhoea of any grade occurred 
in 27–31% of patients receiving ipilimumab [8]. In a 
phase III trial of 511 patients treated with ipilimumab for 
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malignant melanoma, 26 (5%) were hospitalized for se-
vere enterocolitis, 5 (1%) developed intestinal perfora-
tion, and 4 (0.8%) died as a result of complications [5]. In 
a study, enterocolitis was the most frequent irAE associ-
ated with ipilimumab use, occurring in 21% of patients 
[9]. In a multicenter study, the reported incidences of di-
arrhoea, colitis, and grade 3–4 colitis were, respectively, 
54, 22, and 16% [10]. One study found that diarrhoea of 
any grade occurs in approximately 45% of patients on 
combination therapy, 34% of patients on ipilimumab 
monotherapy, and 21% of patients on nivolumab mono-
therapy; with grade 3–4 colitis occurring in 8% of patients 
on combination therapy, 8% of patients on ipilimumab 
monotherapy, and 1% of patients on nivolumab mono-
therapy [11]. PD-1 and PDL-1 inhibitors, either nivolum-
ab or pembrolizumab, seem to be less toxic to the gastro-
intestinal tract than anti-CTLA-4 agents, with grade 3 to 
4 irAEs occurring only in 1–2% of cases [1–3, 5]. Recent 
studies have suggested that patients exposed to nivolum-
ab followed by ipilimumab, or the reverse sequence, who 
developed previous gastrointestinal toxicity with one of 
the drugs do not necessarily do so when subsequently 
treated with the other agent [1, 5]. It is not completely 
understood whether the effect on the frequency and se-
verity of irAEs is dose dependent. A phase II trial demon-
strated an association between the incidence and severity 
of irAEs and increasing ipilimumab dose [7].
Clinical Features
Side effects associated with ICPIs are frequently mild 
and transient. Diarrhoea is the most commonly reported 
gastrointestinal symptom [3, 12]. Watery, nonbloody di-
arrhoea occurs in 19% of patients with anti-PD-1/PD-L1 
therapy and 33% receiving anti-CTLA-4 therapy. Diar-
rhoea and colitis, including severe forms, occur earlier 
and are more frequent with combined anti-CTLA-4 and 
anti-PD-1 agents than with either ipilimumab or anti-
PD-1 [13]. Other presenting symptoms are abdominal 
pain, haematochezia, weight loss, fever, and vomiting [1, 
7, 13]. Anti-CTLA-4-induced enterocolitis may be asso-
ciated with mouth ulcers, anal lesions (fistulas, abscesses, 
fissures), and extra-intestinal manifestations [14]. The 
clinician should be alert to the possibility of colitis when 
bloody diarrhoea is present in conjunction with fever, ab-
dominal pain, or mucus in the stool [12]. Colitis can 
mimic inflammatory bowel disease (IBD) [14]. Diarrhoea 
and colitis severity can be graded according to the Com-
mon Terminology Criteria for Adverse Events (Table 1) 
[13].
Time for colitis development after ICPI administra-
tion has been variable. Onset of gastrointestinal symp-
toms may occur at any time during 1–10 infusions of an-
ti-CTLA-4 [1, 7]. Colitis may even occur several months 
after the last dose of ipilimumab, because the molecular 
effects on CTLA-4 inhibition may persist longer after 
clearance of the drug [7]. Colitis has been reported after 
the first dose of ipilimumab and more than 4 months after 
administration of the last dose [15]. A case series of 19 
patients on anti-PD-1 therapy reported a median time of 
3 months from drug initiation to symptom onset [16].
Less commonly, the upper gastrointestinal tract is in-
volved and clinical manifestations include aphthous ul-
cers, esophagitis, and gastritis [13]. Nausea, vomiting, 
dysphagia, and epigastric pain may be present [1, 17]. 
These symptoms may develop later than those related to 
the lower gastrointestinal tract [18].
Table 1. Common Terminology Criteria for Adverse Events (CTCAE) for diarrhoea and colitis
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Diarrhoea Increase of <4 stools per day 
over baseline; mild increase in 
ostomy output compared to 
baseline
Increase of 4–6 stools per day 
over baseline; moderate increase 
in ostomy output compared to 
baseline; limiting instrumental 
ADL
Increase of ≥7 stools per day 
over baseline; severe increase 
in ostomy output compared to 
baseline; hospitalization 
indicated; limiting self-care 
ADL
Life-threatening 
consequences; urgent 
intervention indicated
Death
Colitis Asymptomatic; clinical or 
diagnostic observations only; 
intervention not indicated
Abdominal pain; mucus or blood 
in stool
Severe abdominal pain; 
peritoneal signs
Life-threatening 
consequences; urgent 
intervention indicated
Death
ADL, activities of daily life. Adapted from the Cancer Therapy Evaluation Program, National Cancer Institute, Common Terminology Criteria for 
Adverse Events (CTCAE) v5.0.
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Diagnosis
The main biological abnormalities in 39 patients with 
anti-CTLA-4 induced enterocolitis were anaemia, in-
creased serum C-reactive protein, and low serum albu-
min levels; faecal calprotectin, measured in 8 patients at 
the time of enterocolitis, was markedly increased [14]. 
The main differential diagnoses of ICPI-induced entero-
colitis are gastrointestinal infections and tumour-related 
symptoms [1]. The initial diagnostics tests should include 
stool analyses for bacterial enteropathogens, parasites, 
and Clostridium difficile toxin [1, 12, 19]. In patients with 
disseminated melanoma, gastrointestinal metastases are 
not rare and should be excluded [1].
A definitive diagnosis of immunotherapy-induced en-
terocolitis must be based on the endoscopic and histo-
pathological evaluation [1, 12, 19]. In the majority of pa-
tients, the sigmoid and the rectum are involved and, 
therefore, a flexible sigmoidoscopy is generally sufficient 
to make the diagnosis. However, in some patients, lesions 
affect only the proximal part of the colon or have a patchy 
distribution. A study of 39 patients with anti-CTLA-4 en-
terocolitis showed that in 38/39 patients (97%) there was 
involvement of the rectum and/or sigmoid, extensive 
colitis was observed in 23/35 patients (66%), and a patchy 
distribution in 18/33 patients (55%). In patients who un-
derwent ileoscopy, ileitis was found in 20% [14]. The na-
ture of intestinal inflammation caused by ICPIs shares 
several morphological features with those seen in IBD [5, 
14, 16, 20]. Endoscopic findings can include oedema, ery-
thema, loss of vascular pattern, erosions, and ulceration 
[1, 3, 5, 14]. In a systematic review of colitis associated 
with anti-CTLA-4 therapy, colonoscopy revealed diffuse 
inflammatory changes such as exudates, granularity, loss 
of vascular pattern, and ulcerations [7].
Clinical correlation and medication history are essen-
tial as in any other drug-related colitis, the histological 
features of colitis associated with ICPIs are non-specific 
and can mimic other forms of colitis such as infectious 
colitis, IBD, ischemic colitis, and other drug-related 
forms of colitis [3]. The vast majority of patients has fea-
tures of an acute colitis, including either focal active coli-
tis with patchy crypt abscesses or diffuse mucosal acute 
inflammation. In some cases, abnormalities consistent 
with chronic IBD such as granulomas, basal plasmocyto-
sis, and crypt abnormalities have been reported [5, 14, 
16]. Anti-CTLA-4 related colitis is characterized by neu-
trophilic inflammation with increased intraepithelial 
lymphocytes, crypt epithelial cell apoptosis, and few or no 
features of chronicity. Anti-PD-1-associated colitis typi-
cally follows one of two patterns: active colitis pattern 
with increased apoptosis (active inflammation, neutro-
philic crypt micro-abscesses, increased crypt epithelial 
cell apoptosis, and presence of crypt atrophy/dropout) or 
a lymphocytic colitis pattern (increased intraepithelial 
lymphocytes in surface epithelium, surface epithelial in-
jury, and expansion of the lamina propria) [12]. Pathol-
ogy with immunohistochemical staining to rule out CMV 
infection is generally recommended in any immunocom-
promised patient with an enterocolitis [16].
Upper gastrointestinal symptoms (dysphagia, epigas-
tric pain…) should prompt upper endoscopy [1, 7]. In a 
French and Belgian multicentric study, of the 22 patients 
with anti-CTLA-4-induced enterocolitis who underwent 
upper endoscopy, one had ulceration of the mid-oesoph-
agus, 9 had gastritis, and 2 had erosive duodenitis. About 
half of the patients with anti-CTLA-4-induced enteroco-
litis have chronic, mild, patchy inflammation of the stom-
ach and the duodenum [14]. The most commonly ob-
served histological changes in the gastric mucosa were 
lamina propria expansion and intraepithelial neutro-
phils; the duodenal and ileal biopsies commonly showed 
lamina propria expansion by lymphoplasmocytic infil-
trates and eosinophils, villous blunting, intraepithelial 
lymphocytes, and neutrophilic villitis [3].
Management
Patients on immunotherapy that develop mild diar-
rhoea can continue ICPI therapy (Fig. 1). Management of 
patients with non-severe diarrhoea is mainly supportive, 
with antidiarrhoeals, fluid, and electrolyte supplementa-
tion. Persistence of grade 2 diarrhoea (defined as four to 
six stools per day for more than 3 days), should prompt 
initiation of 0.5 to 1 mg/kg/day of oral corticosteroids and 
ICPIs should be withheld [2, 3, 5, 13, 19, 21, 22]. The use 
of budesonide seems attractive since it might avoid the 
systemic effects of corticosteroids, though its effect in this 
context seems limited. Loperamide should be withheld to 
avoid the risk of precipitating toxic dilatation. Thrombo-
prophylaxis with low-molecular-weight heparin should 
be initiated since these patients are at increased risk of 
thromboembolism [5]. At this stage, it is advisable to con-
sult gastroenterology specialists and confirm colitis by 
endoscopy and histology, although this approach should 
not delay initiation of corticosteroids. If symptoms do not 
improve with oral corticosteroids, patient hospitalization 
for intravenous (i.v.) corticosteroids should be consid-
ered. Patients with grade 3 and 4 colitis (≥7 stools per day, 
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severe abdominal pain, or complications) require hospi-
talization and should receive treatment with systemic 
corticosteroids (1–2 mg/kg per day, i.v.). If response to 
i.v. corticosteroids is obtained within 3–5 days, they 
should be switched to the oral form and tapered over 8–12 
weeks. Patients that do not improve with this therapy 
within 3–5 days or have a relapse requiring increase in the 
corticosteroid dosage during the course of steroid taper-
ing should be switched to infliximab 5 mg/kg, unless con-
traindicated [3, 5, 13, 14, 19, 23]. Due its severe course, 
patients with immunotherapy-induced enterocolitis 
should be carefully monitored and a rapid escalation to 
infliximab should be advocated in patients who do not 
respond to corticosteroids [14, 23]. Almost all patients 
respond very well to a single dose of infliximab; in some 
cases, a second dose is needed 2 weeks later [14, 19]. 
When a suboptimal response is thought to be due to ex-
cessive enteral losses from inflamed gut, administering 
the drug sooner or at a higher dose (10 mg/kg) should be 
considered [5]. Vedolizumab is a humanized monoclonal 
IgG1 antibody against α4β7 integrin, approved for treat-
ment of IBD. Some case reports suggest that vedolizumab 
may be an effective drug in steroid-refractory or steroid-
dependent patients [24, 25]. A recent study with seven 
patients with mild to moderate, steroid-dependent or ste-
roid-refractory ipilimumab-induced enterocolitis has re-
vealed that six out of seven patients treated with vedoli-
zumab achieve remission and no adverse events were re-
ported [26]. Neither corticosteroids nor infliximab appear 
to influence response and survival of patients treated with 
ICPIs [1]. When a severe life-threatening enterocolitis 
develops, irresponsive to any medical treatment, which 
may result in perforation of the intestine, colectomy with 
ileostomy should be performed [1, 5]. Restarting the im-
Oral prednisone 0.5–1 mg/kg/day
Schedule sigmoidoscopy/colonoscopy but do
not wait to start treatment
Oral fluids, electrolyte replacement,
antidiarrhoeal agents
Management
If G1 persists >14 days or G2 persists
>3 days or worsens
i.v. methylprednisone 1–2 mg/kg/day followed
by oral prednisone taper over 8–12 weeks
Gastroenterology consultation
If no improvement in 72 h or worsening
or absorption concern
Infliximab 5 mg/kg (if no contraindications)
If no improvement, it can be repeated 2 weeks later
Prior sigmoidoscopy/colonoscopy is necessary
If no improvement in 72 h or worsening
Moderate (G2)
Outpatient management if appropriate
If unwell, manage as per severe
ICPI to be withheld
Mild (G1)
ICPI can be continued
Symptom grade
Severe (G3/4)
Inpatient management
ICPI to be withheld
Steroid wean duration:
• Moderate: 2–4 weeks
• Severe: 4–8 weeks
Steroids >4 weeks:
• Consider PJP prophylaxis, calcium/vitamin D
 supplement
Fig. 1. Management of gastrointestinal toxicity of immune checkpoint inhibitors.
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munotherapy after successful management of the entero-
colitis poses a high risk of relapse and should always be 
individualized. Usually, in grade 3 and 4 colitis, ICPI 
therapy is often permanently discontinued [1, 13, 19].
Conclusion
The discovery of immune checkpoint proteins was a 
major breakthrough in cancer immunotherapy, which 
significantly impacted the management of patients with 
solid organ and hematopoietic malignancies. ICPIs are 
becoming an increasingly more common therapeutic ap-
proach in patients with advanced malignancy as a grow-
ing number of new ICPI agents are being subjected to 
clinical evaluation in numerous types of tumours; subse-
quently, the prevalence of ICPI-related adverse events 
may be expected to increase considerably in the near fu-
ture. Gastroenterologists must be aware of these drugs, 
their gastrointestinal adverse event profiles, and how to 
manage them, taking the long-term cancer treatment 
strategy and the overall survival into account. Early rec-
ognition of the disease and close collaboration between 
oncologists, gastroenterologists, and surgeons is manda-
tory for optimal management of these patients.
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